相关实验视频
Updated: May 13, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
9.7K
关于不同品种山姆的营养特征和抗高血糖活性成分的全面评估
Yuzheng Lin1,2, Li Qu1, Mengting Zhang1
1School of Nursing, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian Province, China.
Scientific reports
|April 12, 2025
概括
这项研究使用先进的方法评估了的质量,发现铁优越. 紫因其活性化合物而显示出降血糖产品的前景.
科学领域:
- 农业科学 农业科学
- 食品化学 食品化学
- 营养科学 营养科学
背景情况:
- 是一种重要的作物,具有药用和食用途,特别是在中国德华县.
- 诸如清和紫等公认的山品种有地理标志,但缺乏全面的质量评估.
- 这项研究解决了对Dehua的系统质量评估的需求.
研究的目的:
- 综合分析三个山姆品种的营养和低血糖活性成分.
- 建立一个使用正宗药品"铁"的质量基准.
- 为了确定 yam 类型之间的质量指标的相关性和差异.
主要方法:
- 使用了高性能液态色谱 (HPLC),紫外线光谱和火焰原子吸收光谱.
- 应用统计分析包括描述性统计,相关性分析,主要组件分析 (PCA),部分最小平方差分分析 (PLS-DA),集群分析和多重线性回归.
- 使用"铁"作为质量比较的基准.
主要成果:
- 在三种山姆品种中观察到营养和活性成分度的显著差异.
- 确定了65个高度相关的和39个统计学上显著的指标对.
- 主要成分分析表明"铁"具有最有利的整体质量.
结论:
- 玉米的质量有很大的差异,而"铁玉米"作为高质量的基准.
- 紫因其丰富的活性化合物而具有开发低血糖产品的高潜力.
- 这项研究为以质量为基础的种植和产品开发提供了基础.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
124
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
124
Oral Hypoglycemic Agents: Glinides
111
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
111
Oral Hypoglycemic Agents: Biguanides and Glitazones
141
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
141
Hypoglycemia and Glucagon
142
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
142
Diabetes: Symptoms, Diagnosis, and Complications
485
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
485
Dipeptidyl Peptidase 4 Inhibitors
134
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
134

